越川 真行

Medicine & Life Sciences

1. Albumins 13%
2. Anticoagulants 38%
3. apixaban 8%
4. Aspirin 14%
5. Atrial Appendage 20%
6. Atrial Fibrillation 100%
7. Brain Natriuretic Peptide 14%
8. Cardiovascular Diseases 11%
9. Catheter Ablation 17%
10. Cicatrix 8%
11. Cohort Studies 10%
12. Creatinine 7%
13. Dabigatran 26%
14. Echocardiography 13%
15. edoxaban 9%
16. Elderly 10%
17. Embolism 8%
18. Factor Xa Inhibitors 13%
19. Gadolinium 10%
20. Heart Atria 12%
21. Heart Failure 24%
22. Hemorrhage 18%
23. Heparin 8%
24. Hospital Mortality 15%
25. IgA receptor 7%
26. Incidence 7%
27. Inflammation 9%
28. International Normalized Ratio 18%
29. Left Ventricular Dysfunction 6%
30. Lower Extremity 6%
31. Magnetic Resonance Imaging 8%
32. Mortality 8%
33. Multivariate Analysis 6%
34. Muscle Strength 8%
35. N(4)-oleylcytosine arabinoside 10%
36. Prospective Studies 10%
37. Proteolysis 15%
38. Pulmonary Veins 18%
39. Rivaroxaban 29%
40. ROC Curve 6%
41. Safety 9%
42. Sarcoidosis 17%
43. Serum Albumin 16%
44. Skeletal Muscle 12%
45. Stroke Volume 14%
46. Systolic Heart Failure 21%
47. Takotsubo Cardiomyopathy 22%
48. Thromboembolism 21%
49. Thrombosis 14%
50. Warfarin 19%